Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
November 27, 2024 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Announces Leadership Transition Plan With Industry Veterans
November 14, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong
November 04, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3
October 30, 2024 08:00 ET
|
Windtree Therapeutics
After successful SEISMiC A and B studies in Early Cardiogenic Shock, SEISMiC C will treat more severe SCAI Stage C cardiogenic shock to complete the assessment of the intended Phase 3 patient...
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
October 23, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree To Present at the ThinkEquity Conference on October 30th
October 21, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
October 17, 2024 08:15 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design
October 09, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
September 30, 2024 08:15 ET
|
Windtree Therapeutics
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias NYHA heart...
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
September 26, 2024 16:05 ET
|
Windtree Therapeutics
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree’s strategy and planned near-term...